Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fifty-Two Weeks, Open Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002

Next Previous
Trial Profile

Fifty-Two Weeks, Open Label Extension Trial to Evaluate Safety and Efficacy of Org 50081 in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 176001 or 176002

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Esmirtazapine (Primary)
  • Indications Insomnia
  • Focus Adverse reactions
  • Sponsors Merck Sharp & Dohme

Most Recent Events

  • 20 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 20 Jan 2010 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
  • 09 Oct 2009 Schering-Plough added as trial sponsor and affiliate as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top